Stock Analysts

LabCorp (LH) Q4 Earnings Beat Estimates, ’18 View Promising

Laboratory Corporation of America Holdings LH or LabCorp reported fourth-quarter 2017 adjusted earnings per share (EPS) of $2.45, up 13.9% from the year-ago quarter. The bottom line also exceeded the Zacks Consensus Estimate by 3.4%. One-time benefit related to the Tax Cuts and Jobs Act in the reported quarter, affected adjusted EPS by 5 cents, approximately […]

Stock Analysts

BP plc (BP) Q4 Earnings Miss Estimates, Skyrocket Y/Y

BP plc BP reported a year-over-year rise in fourth-quarter 2017 earnings, courtesy of record oil and gas production and higher commodity price realizations. Increased refinery throughput also drove earnings, partially offset by increased exploration expenses. Royal Dutch Shell RDS.A is another European energy giant that reported a significant hike in fourth-quarter profits on Feb 1 […]

Stock Analysts

NVIDIA’s Gaming Segment to Gain From Higher GPU Adoption

All eyes will be on NVIDIA Corporation NVDA this week as investors continue to expect an overwhelming quarterly report from the company’s fourth-quarter fiscal 2018 results. For the last two years, this graphic chipmaker has impressed investors with its stellar performance, wherein the company’s quarterly revenues have been advancing at a rate more than 50%, earnings have tripled and shares have displayed more than six-fold growth, consequently. Although new markets, including datacenter, autonomous vehicle and cryptocurrency will continue to record increase in revenue contribution, the company’s gaming business remains the core segment on which its overall growth depends […]

Stock Analysts

Spectrum Pharma’s Rolontis Positive in Pivotal Cancer Study

Spectrum Pharmaceuticals, Inc. SPPI announced positive data from a phase III study, ADVANCE, evaluating its lead pipeline candidate, Rolontis, for management of chemotherapy-induced neutropenia in patients with early-stage breast cancer. The candidate demonstrated non-inferiority to Amgen Inc.’s AMGN Neulasta in improving duration of severe neutropenia […]

Stock Analysts

Archer Daniels (ADM) Q4 Earnings Top Estimates, Revenues Lag

Archer Daniels Midland Company ADM reported mixed fourth-quarter 2017 results, wherein the bottom line topped the Zacks Consensus Estimate while the top line missed the same. With this, the company retains its more than three-year long trend of sales misses. Following the quarterly results, the company’s shares dipped 1.2% in the pre-market trading session […]

Stock Analysts

Bristol-Myers’ Opdivo/Yervoy Combo Positive in Cancer Study

Bristol-Myers Squibb Company BMY announced that its PD-1 immune checkpoint inhibitor, Opdivo, in combination with Yervoy, demonstrated superiority in improving progression free survival (“PFS”) in a phase III lung cancer study. The positive data again showed the blockbuster potential of Opdivo, which is already approved in multiple indications and is also being evaluated in several others. Shares of the company have returned 18% in the past year, outperforming the industry ’s gain of 13.8% in that period […]

Stock Analysts

AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

AmerisourceBergen Corporation ABC posted adjusted earnings of $1.55 per share in the first quarter of fiscal 2018, beating the Zacks Consensus Estimate of $1.35 and improving 14% year over year. The upside can be attributed to strong growth in the company’s Pharmaceutical Distribution Segment and World Courier business. […]

Stock Analysts

Allergan (AGN) Q4 Earnings Beat on Increase in Botox Sales

Allergan plc ’s AGN fourth-quarter 2017 earnings came in at $4.86 per share, beating the Zacks Consensus Estimate of $4.74 by 2.5%. Earnings rose 24.6% year over year driven by higher revenues and lower R&D costs. Revenues came in at $4.33 billion, which beat the Zacks Consensus Estimate of $4.28 billion by 1.2%. […]